TGF-β antagonists: same knot, but different hold

Area of Science:

• Biochemistry
• Structural Biology
• Molecular Biology

Background:

• Bone morphogenetic proteins (BMPs) are crucial signaling molecules involved in various developmental processes.
• Dysregulation of BMP signaling is implicated in numerous diseases, including cancer and skeletal disorders.
• Antagonists of the transforming growth factor-beta (TGF-β) superfamily regulate BMP activity.

Purpose of the Study:

• To elucidate the three-dimensional structure of PRDC (also known as PRGPIA), a novel antagonist of BMP signaling.
• To characterize the unique structural features and inhibitory mechanism of the PRDC dimer.
• To compare the structure and function of PRDC with other known dimeric BMP antagonists, such as noggin.

Main Methods:

• X-ray crystallography was employed to determine the high-resolution structure of PRDC.
• Biochemical assays were used to assess the inhibitory activity of PRDC against BMP signaling.
• Comparative structural analysis was performed between PRDC and other TGF-β superfamily antagonists.

Main Results:

• PRDC forms a stable head-to-tail dimer, a distinct quaternary structure compared to other dimeric antagonists.
• The dimeric interface and overall fold of PRDC are unique, suggesting a novel inhibitory mechanism.
• Structural comparisons reveal significant differences in the ligand-binding interfaces and conformational states between PRDC and noggin.

Conclusions:

• The study presents the first structural insights into the BMP antagonist PRDC.
• PRDC's unique head-to-tail dimeric structure underlies its distinct inhibitory mechanism.
• These findings provide a foundation for understanding PRDC's role in BMP signaling and its potential as a therapeutic target.